ArticleAntiviral research2009
Procyanidins and butanol extract of Cinnamomi Cortex inhibit SARS-CoV infection.
Article in Antiviral research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 3 syntheses or guidelines pooled it, 165 citations in OpenAlex.
- Effect of herbal compounds on coronavirus; a systematic review and meta-analysis.Virology journal · 2022Pooled it
- Promising Antiviral Activities of Natural Flavonoids against SARS-CoV-2 Targets: Systematic Review.International journal of molecular sciences · 2021Pooled it
- Phytochemicals against SARS-CoV as potential drug leads.Biomedical journal · 2021Pooled it
- Review
- A critical review on phytochemicals as antiviral medications for SARS-CoV-2 virus infection.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- The Novel A-Type Proanthocyanidin-Rich Phytocomplex SP4™ Acts as a Broad-Spectrum Antiviral Agent against Human Respiratory Viruses.International journal of molecular sciences · 2024Article
- Ayurvedic and Chinese Herbs against Coronaviruses.Current pharmaceutical design · 2024Review
- Antiviral Activity of Natural Herbs and their Isolated BioactiveCompounds: A Review.Combinatorial chemistry & high throughput screening · 2024Review
- Identification of natural compounds (proanthocyanidin and rhapontin) as high-affinity inhibitors of SARS-CoV-2 Mpro and PLpro using computational strategies.Archives of medical science : AMS · 2024Article
- Repurposing of Plant-based Antiviral Molecules for the Treatment of COVID-19.Current topics in medicinal chemistry · 2024Review
- An overview on medicinal plants used for combating coronavirus: Current potentials and challenges.Journal of agriculture and food research · 2023Article
- An Attention towards the Prophylactic and Therapeutic Options of Phytochemicals for SARS-CoV-2: A Molecular Insight.Molecules (Basel, Switzerland) · 2023Review
- Spices and Biomarkers of COVID-19: A Mechanistic and Therapeutic Perspective.Advances in experimental medicine and biology · 2023Review
- Phytomedicines explored underSouth African journal of botany : official journal of the South African Association of Botanists = Suid-Afrikaanse tydskrif vir plantkunde : amptelike tydskrif van die Suid-Afrikaanse Genootskap van Plantkundiges · 2022Review
- Tackling the Future Pandemics: Broad-Spectrum Antiviral Agents (BSAAs) Based on A-Type Proanthocyanidins.Molecules (Basel, Switzerland) · 2022Review
- Phytochemical Analysis, Antioxidant, and Antimicrobial Activities ofAntioxidants (Basel, Switzerland) · 2022Article
- Quercetin in the Prevention and Treatment of Coronavirus Infections: A Focus on SARS-CoV-2.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Evaluation of the anti-SARS-CoV-2 properties of essential oils and aromatic extracts.Scientific reports · 2022Article
- Total Synthesis of Parameritannin A2, a Branched Epicatechin Tetramer with Two Double Linkages.Angewandte Chemie (International ed. in English) · 2022Article
- Antiviral Activity of Medicinal Plants against Human Coronavirus: a systematic scoping review of and experimentations.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2022Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We found that the butanol fraction of Cinnamomi Cortex (CC/Fr.2) showed moderate inhibitory activity in wild-type severe acute respiratory syndrome coronavirus (wtSARS-CoV) and HIV/SARS-CoV S pseudovirus infections. The inhibition on pseudovirus was also seen in cells pretreated with the CC and CC/Fr.2 (IC(50S), 283.4+/-16.3 and 149.5+/-13.5 microg/ml, respectively), however the highest activities on wtSARS-CoV were observed when the viruses were treated by the extracts before challenging (IC(50S), 43.1+/-2.8 and 7.8+/-0.3 microg/ml; SIs, 8.4 and 23.1, respectively). Among the compounds fractionated from CC, procyanidin A2 and procyanidin B1 showed moderate anti-wtSARS-CoV activity (IC(50S), 29.9+/-3.3 and 41.3+/-3.4 microM; SIs, 37.35 and 15.69, respectively). We also sought to determine whether they could interfere with the clathrin-dependent endocytosis pathway using transferrin receptor (TfR) as an indicator. CC/Fr.2 inhibited the internalization of TfR but the procyanidins did not. Taken together, CC/Fr.2 contains unknown substances, that could inhibit the infection, probably by interfering with endocytosis, and it also contains procyanidins that did not inhibit the internalization but inhibited the infection. Therefore, CC extracts contain anti-virus activities that act through distinct mechanisms according to differences in the compounds or mixtures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.